← Leaderboards
Amanda Pattison
Thomas Jefferson University
$111,860
Attributed
$111,860
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $45K · FY2018–20$50K$37.5K$25K$12.5K$0
'18
'19
'20
Funding mix
By agency
NIH$111,860 · 1
By mechanism
F31$111,860 · 1
Top collaborators
No co-investigators on record.
Most similar at Thomas Jefferson University
Same institution · by research overlap
- Scott A. Waldman$27,830,994
- Judith L Ross$14,102,456
- David S Weinberg$9,421,275
- Giancarlo Ghiselli$1,122,822
- Joshua R Barton$174,828
Others in their field
Other Emerging Leaders on “Adjuvant Therapy”
- Wendy Sammons-Jackson · National Institute Of Allergy And Infectious Diseases$10,000,000
- Jean Kwun · Duke University$5,686,708
- Patrick R Secor · University Of Montana$4,394,600
- Holly Rockweiler · Madorra, Inc.$4,300,000
- Kenneth B. Bader · University Of Chicago$4,178,329
- Alexandra Margaret Lynn Binder · University Of California Los Angeles$4,065,524
Research focus
Adjuvant TherapyAllelesAntitumor EffectAttenuatedBaseBeta CateninCancer ChemopreventionCancer EtiologyCarcinomaCell NucleusCessation Of LifeChemopreventionChemopreventive AgentChronicColon Cancer PatientsColon TumorigenesisColorectalColorectal AdenomaColorectal CancerColorectal Cancer PreventionColorectal Cancer RiskColorectal Cancer TreatmentColorectal NeoplasmsAdenoma
Grant awards (3)
Reactivating the GUCY2C signaling axis opposes oncogenic B-catenin for cancer chemoprevention$22,320
F31 · FY2020 · CA · contact PI
Reactivating the GUCY2C signaling axis opposes oncogenic B-catenin for cancer chemoprevention$45,016
F31 · FY2019 · CA · contact PI
Reactivating the GUCY2C signaling axis opposes oncogenic B-catenin for cancer chemoprevention$44,524
F31 · FY2018 · CA · contact PI